Soligenix announces formation of behÇet's disease medical advisory board

Phase 2a clinical study of sgx945 in behÇet's disease initiating in 2024 princeton, n.j. , feb. 8, 2024 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the formation of a medical advisory board (mab) to provide medical/clinical strategic guidance to the company as it advances the clinical development of sgx945 (dusquetide) for the treatment of behÇet's disease.
SNGX Ratings Summary
SNGX Quant Ranking